- Home
- KTTA vs OCEAW Comparison
KTTA vs OCEAW Comparison
Compare KTTA & OCEAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KTTA
- OCEAW
- Stock Information
- Founded
- KTTA 2020
- OCEAW N/A
- Country
- KTTA United States
- OCEAW United States
- Employees
- KTTA N/A
- OCEAW 7
- Industry
- KTTA Biotechnology: Pharmaceutical Preparations
- OCEAW Biotechnology: Pharmaceutical Preparations
- Sector
- KTTA Health Care
- OCEAW Health Care
- Exchange
- KTTA Nasdaq
- OCEAW Nasdaq
- Market Cap
- KTTA N/A
- OCEAW N/A
- IPO Year
- KTTA 2021
- OCEAW 2021
- Fundamental
- Price
- KTTA $1.73
- OCEAW $0.02
- Analyst Decision
- KTTA
- OCEAW
- Analyst Count
- KTTA 0
- OCEAW 0
- Target Price
- KTTA N/A
- OCEAW N/A
- AVG Volume (30 Days)
- KTTA 5.3M
- OCEAW N/A
- Earning Date
- KTTA 05-13-2025
- OCEAW N/A
- Dividend Yield
- KTTA N/A
- OCEAW N/A
- EPS Growth
- KTTA N/A
- OCEAW N/A
- EPS
- KTTA N/A
- OCEAW N/A
- Revenue
- KTTA N/A
- OCEAW N/A
- Revenue This Year
- KTTA N/A
- OCEAW N/A
- Revenue Next Year
- KTTA N/A
- OCEAW N/A
- P/E Ratio
- KTTA N/A
- OCEAW N/A
- Revenue Growth
- KTTA N/A
- OCEAW N/A
- 52 Week Low
- KTTA $0.92
- OCEAW N/A
- 52 Week High
- KTTA $7.69
- OCEAW N/A
- Technical
- Relative Strength Index (RSI)
- KTTA 64.02
- OCEAW N/A
- Support Level
- KTTA $1.30
- OCEAW N/A
- Resistance Level
- KTTA $1.81
- OCEAW N/A
- Average True Range (ATR)
- KTTA 0.24
- OCEAW 0.00
- MACD
- KTTA 0.05
- OCEAW 0.00
- Stochastic Oscillator
- KTTA 53.08
- OCEAW 0.00
About OCEAW Ocean Biomediacal Inc.
Ocean Biomedical Inc is a biopharmaceutical company that is focused on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome.